Schering-Plough, the drug company known for its cholesterol treating drugs Vytorin™
recently announced a merger with Merck, a drug company known for asthma and allergy medicine Singulair®
. This news might be interesting for us because these companies are also involved in developing drugs for treating or preventing viral hepatitis infection. For example, Schering-Plough makes Pegintron (a pegylated interferon
for treating chronic hepatitis C
) and Merck has developed hepatitis vaccines for HAV
. For those of you who may be concerned on the effect this merger will have on hepatitis drugs, I think this is ultimately seen as a good thing. Mergers like this have happened before with positive results (Schering-Plough, itself, bought Organon BioSciences not too long ago and Pfizer acquired Wyeth). According to the company press release
, this merger will be beneficial to both companies, creating stronger research and manufacturing opportunities.